Study: Many cancer drugs unproven 5 years after accelerated approval
Time:2024-05-21 12:09:26 Source:styleViews(143)
The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?
In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years.
“Five years after the initial accelerated approval, you should have a definitive answer,” said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not.”
The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs.
It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce better evidence before gaining full approval.
Previous:Fresh heartache for cancer
Next:Jessica Biel CHOPS her long locks into a bob after book signing in Studio City
You may also like
- Russian theater director and playwright go on trial over a play authorities say justifies terrorism
- Nation urged to make greater use of geothermal energy
- Huawei Indonesia opens 5G center to boost digital transformation technologies
- Discount retailers making mark among price
- College baseball notebook: Conference tournaments to decide NCAA automatic bids and many at
- CRCC equipment renewal campaign spurring growth of circular economy
- Xiong'an eyes hub of innovation, startups
- Remains of Li Keqiang Cremated in Beijing
- The government wants to buy their flood